Zura Bio Limited announced that on April 6, 2023, Preston Klassen notified that he intended to resign as the Company's President and Chief Operating Officer. Dr. Klassen's last day of employment at the Company will be April 11, 2023. Chris Cabell, the Company's Chief Medical Officer and Executive Vice President, will be taking on Dr. Klassen's duties going forward.

Prior to joining the Company in February 2023, Dr. Klassen served as President and Chief Executive Officer of Metacrine Inc. from June 2020 to February 2023 and as a member of its Board of Directors from June 2020 to March 2023. From March 2017 to June 2020, Dr. Klassen served as Executive Vice President, Head of Research and Development and Chief Medical Officer of Arena Pharmaceuticals Inc., a biopharmaceutical company. From June 2016 to March 2017, he was Chief Medical Officer of Laboratoris Sanifit S.L., a biotechnology company.

From November 2009 to May 2016, Dr. Klassen served as Executive Vice President, Head of Global Development at Orexigen Therapeutics Inc., which filed a voluntary Chapter 11 petition in the United States Bankruptcy Court for the District of Delaware in March 2018.